2023
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Aggarwal S, Espinosa S. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2023, 21: 1224-1233. PMID: 38081139, DOI: 10.6004/jnccn.2023.0062.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN guidelinesNCCN Guidelines InsightsSystemic therapy recommendationsAdvanced cervical cancerMetastatic diseaseTreatment landscapeClinical outcomesDiagnostic workupHistopathologic classificationTherapy recommendationsCancerMolecular profileAspects of managementRecent updatesDiagnostic featuresGuidelinesWorkupStagingDiseaseRecurrentPathology
2020
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 660-666. PMID: 32502976, DOI: 10.6004/jnccn.2020.0027.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN Guidelines InsightsSystemic therapy recommendationsTreatment of patientsHistopathologic classification systemNCCN guidelinesMetastatic diseaseDiagnostic workupEndocervical adenocarcinomaTherapy recommendationsPatientsCancerDiseaseRecent updatesClassification systemGuidelinesHPVAdenocarcinomaWorkupStagingRecurrent
2019
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 64-84. PMID: 30659131, DOI: 10.6004/jnccn.2019.0001.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCervix UteriChemoradiotherapy, AdjuvantFemaleFertility PreservationHumansHysterectomyMass ScreeningMedical OncologyNeoplasm StagingOrgan Sparing TreatmentsPapanicolaou TestPapillomaviridaePapillomavirus InfectionsSocieties, MedicalUnited StatesUterine Cervical NeoplasmsConceptsCervical cancerHuman papilloma virus vaccinationNCCN Clinical Practice GuidelinesTreatment of recurrentAdvanced cervical cancerClinical practice guidelinesMalignant epithelial tumorsNCCN guidelinesMetastatic diseaseVirus vaccinationUterine cervixCommon cancerPrecancerous lesionsFull guidelinePractice guidelinesEpithelial tumorsRoutine screeningCancerScreening protocolTreatmentGuidelinesMost casesEarly stagesCervixVaccination
2015
Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer
Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.Peer-Reviewed Original ResearchConceptsBrain metastatic diseaseEpithelial ovarian cancerBrain metastasesEndometrial cancerCervical cancerGynecologic cancerSurgical resectionTwo-year overall survival ratesLargest single-institution experienceSingle institution experienceOverall survival rateOverall survival dataMedian survival timeSignificant hazard ratioLong-term survivalHazard ratioMetastatic diseaseOverall survivalImproved survivalRetrospective reviewIntracranial metastasesPalliative carePoor prognosisCancer increasesFactors Predictive